On Friday, Maxim Integrated Products Inc. (NASDAQ:MXIM)’s shares inclined 1.90% to $33.29.
Maxim Integrated Products, Inc. (MXIM) will declare fiscal first quarter 2016 results after market close on Thursday, October 22, 2015. The full release will be accessible at www.maximintegrated.com/company/investor.
Maxim Integrated Products, Inc. designs, develops, manufactures, and markets various linear and mixed-signal integrated circuits worldwide. The company also provides a range of high-frequency process technologies and capabilities for use in custom designs. It primarily serves automotive, communications and data center, computing, consumer, and industrial markets.
AstraZeneca plc (ADR) (NYSE:AZN)’s shares gained 1.01% to $32.11.
Results from a US comparative effectiveness study of two maintenance treatment options for patients with a history of chronic obstructive pulmonary disease (COPD) were published recently in the International Journal of COPD. This is the first US real-world study to examine the comparative effectiveness of SYMBICORT® 160/4.5 (budesonide/formoterol fumarate dihydrate) Inhalation Aerosol, an inhaled corticosteroid and long-acting beta2-agonist combination therapy, and tiotropium bromide 18 mcg, a long-acting muscarinic antagonist, in patients with COPD.
The study was conducted using US claims data from the HealthCore Integrated Research Environment. The analysis comprised of patients who were at least 40 years old and had a diagnosis code for COPD associated with either hospitalization, treatment in an emergency department, and/or fill of an oral corticosteroid prescription within 10 days of an outpatient visit. Patients were followed for 12 months after an initial prescription fill for either SYMBICORT or tiotropium bromide. Comparative effectiveness between the two study cohorts comprised of analysis of healthcare utilization and costs in the year following an initial prescription claim.
AstraZeneca PLC engages in the discovery, development, and commercialization of prescription medicines for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection, and neuroscience diseases worldwide. Its products comprise Crestor for dyslipidaemia and hypercholesterolemia; Seloken/Toprol-XL to control hypertension, and heart failure and angina; Onglyza for diabetes mellitus; Iressa for non-small cell lung cancer; Faslodex for breast cancer in post-menopausal women; Zoladex for prostate cancer, breast cancer, and certain benign gynaecological disorders; Pulmicort Turbuhaler/Pulmicort Flexhaler for treating asthma; Symbicort for maintenance treatment of asthma and chronic obstructive pulmonary disease; Nexium to treat acid-related diseases; Seroquel XR for the treatment of schizophrenia, bipolar disorder, major depressive disorder, and generalised anxiety disorder; and Synagis for the prevention of serious lower respiratory tract disease caused by respiratory syncytial virus in paediatric patients.
At the end of Friday’s trade, Owens-Illinois Inc (NYSE:OI)‘s shares surged 2.44% to $21.40.
Owens-Illinois, Inc. (OI) has planned its third quarter 2015 conference call and webcast for Wednesday, Oct. 28, 2015, at 8 a.m. EST. The company`s news release for the third quarter 2015 earnings will be issued after the market closes on Tuesday, Oct. 27.
Owens-Illinois, Inc., through its auxiliaries, manufactures and sells glass container products to food and beverage manufacturers primarily in Europe, North America, South America, and the Asia Pacific.
U.S. Silica Holdings Inc (NYSE:SLCA), ended its Friday’s trading session with 5.01% gain, and closed at $14.47.
U.S. Silica Holdings, Inc. declared the introduction of InnoProp® Python RCS, a new high-performance resin coated proppant designed to enhance the production of oil and gas wells in an economical and efficient manner. Independent tests confirm that InnoProp® Python resin coated sand prevents proppant flowback to the well-bore with high-end conductivity and strength. With U.S. Silica’s extensive network of transloads and access to Class-1 railroads, InnoProp® Python resin coated sand can be delivered to locations within 100 miles of more than 80% of recently’s active drilling rigs.
InnoProp® Python RCS is accessible in all mesh sizes utilized in recently’s frac designs and is recommended in all formations with net closure stresses up to 10,000 psi.
U.S. Silica Holdings, Inc. produces and sells commercial silica in the United States. It operates through two segments, Oil & Gas Proppants, and Industrial & Specialty Products. The company offers whole grain commercial silica products to be used as fracturing sand in connection with oil and natural gas recovery, in addition to sells its whole grain silica products in various size distributions, grain shapes, and chemical purity levels for manufacturing glass products.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
